Blood pressure effects of canagliflozin and clinical outcomes in Type 2 diabetes and chronic kidney disease
In post hoc analysis of CREDENCE RCT (n=4401), canagliflozin reduced systolic BP by 3.50 mm Hg (95% CI, –4.27 to –2.72) by week 3 & this was maintained over the duration of the trial with similar reductions across BP and BP-lowering therapy subgroups.
Source:
Circulation
SPS commentary:
Commentary is provided on the recent large, randomised controlled clinical trials demonstrating that treatment with SGLT2 inhibitors significantly reduces the rate of cardiovascular events (including heart failure) and prevents the progression of renal dysfunction (and ultimately chronic kidney disease) in patients with or without diabetes who were already receiving optimal guideline-directed medical therapy